Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosseti Center reported for 6 months of 2023 by RAS

7/31/23 MRKC

MGTS reported for 6 months of 2023 by RAS

7/31/23 MGTS

United Medical Group intends to redomicile to Oktyabrsky Island

7/31/23 GEMC

Whoosh trips have nearly doubled since the beginning of the year

7/31/23 WUSH

UTair reported for 6 months of 2023 by RAS

7/31/23 UTAR

TNS Energo Yaroslavl reported for 6 months of 2023 by RAS

7/31/23 YRSB

Rostelecom launched a marketplace of services for small and medium-sized businesses

7/31/23 RTKM

Krasnoyarskenergosbyt reported for 6 months of 2023 by RAS

7/31/23 KRSB

Permenergosbyt reported for 6 months of 2023 by RAS

7/31/23 PMSB

TNS Energo Nizhny Novgorod reported for 6 months of 2023 by RAS

7/31/23 NNSB